London Company of Virginia’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Sell
2,378
-1,491
-39% -$172K ﹤0.01% 159
2025
Q4
$407K Sell
3,869
-850
-18% -$79.8K ﹤0.01% 161
2025
Q3
$396K Sell
4,719
-1,475
-24% -$121K ﹤0.01% 161
2025
Q2
$490K Sell
6,194
-8,648
-58% -$687K ﹤0.01% 156
2025
Q1
$1.33M Sell
14,842
-2,152,170
-99% -$201M 0.01% 139
2024
Q4
$216M Sell
2,167,012
-161,330
-7% -$16.6M 1.18% 37
2024
Q3
$264M Sell
2,328,342
-169,750
-7% -$20.2M 1.39% 24
2024
Q2
$309M Sell
2,498,092
-123,818
-5% -$15.9M 1.74% 18
2024
Q1
$346M Sell
2,621,910
-104,038
-4% -$12.8M 1.82% 16
2023
Q4
$297M Sell
2,725,948
-197,464
-7% -$20.5M 1.67% 20
2023
Q3
$301M Sell
2,923,412
-108,757
-4% -$11.7M 1.81% 18
2023
Q2
$350M Sell
3,032,169
-75,855
-2% -$8.61M 1.98% 11
2023
Q1
$331M Sell
3,108,024
-99,335
-3% -$10.7M 1.91% 13
2022
Q4
$356M Buy
3,207,359
+9,898
+0.3% +$1.01M 2.1% 13
2022
Q3
$275M Buy
3,197,461
+111,272
+4% +$9.93M 1.74% 19
2022
Q2
$281M Sell
3,086,189
-117,109
-4% -$10.4M 1.72% 18
2022
Q1
$263M Buy
3,203,298
+113,778
+4% +$8.97M 1.39% 27
2021
Q4
$237M Sell
3,089,520
-7,153
-0.2% -$570K 1.19% 34
2021
Q3
$233M Buy
3,096,673
+85,396
+3% +$6.49M 1.28% 34
2021
Q2
$234M Sell
3,011,277
-126,866
-4% -$9.44M 1.25% 35
2021
Q1
$231M Sell
3,138,143
-2,668
-0.1% -$197K 1.32% 32
2020
Q4
$245M Buy
3,140,811
+41,184
+1% +$3.15M 1.53% 25
2020
Q3
$245M Buy
3,099,627
+9,948
+0.3% +$779K 1.75% 19
2020
Q2
$228M Buy
3,089,679
+69,748
+2% +$5.25M 1.77% 20
2020
Q1
$222M Sell
3,019,931
-114,084
-4% -$8.97M 2.12% 11
2019
Q4
$272M Sell
3,134,015
-42,552
-1% -$3.5M 2.1% 10
2019
Q3
$255M Sell
3,176,567
-19,006
-0.6% -$1.52M 2.1% 11
2019
Q2
$256M Buy
3,195,573
+12,964
+0.4% +$993K 2.2% 9
2019
Q1
$253M Sell
3,182,609
-35,282
-1% -$2.64M 2.16% 10
2018
Q4
$235M Sell
3,217,891
-252,415
-7% -$17.8M 2.24% 9
2018
Q3
$235M Sell
3,470,306
-69,638
-2% -$4.44M 1.83% 17
2018
Q2
$205M Sell
3,539,944
-44,245
-1% -$2.5M 1.67% 19
2018
Q1
$186M Sell
3,584,189
-347,989
-9% -$18.8M 1.49% 27
2017
Q4
$211M Sell
3,932,178
-397,063
-9% -$22M 1.53% 25
2017
Q3
$265M Sell
4,329,241
-103,295
-2% -$6.26M 1.9% 13
2017
Q2
$271M Buy
4,432,536
+146,539
+3% +$8.92M 1.84% 13
2017
Q1
$260M Buy
4,285,997
+229,381
+6% +$13.9M 1.71% 13
2016
Q4
$228M Buy
4,056,616
+537,631
+15% +$31.5M 1.57% 19
2016
Q3
$210M Buy
3,518,985
+312,654
+10% +$18.3M 1.57% 20
2016
Q2
$176M Buy
3,206,331
+313,215
+11% +$16.7M 1.36% 27
2016
Q1
$146M Buy
2,893,116
+2,879,581
+21,275% +$141M 1.2% 38
2015
Q4
$682K Sell
13,535
-681
-5% -$34.3K 0.01% 113
2015
Q3
$670K Sell
14,216
-383
-3% -$20.3K 0.01% 114
2015
Q2
$793K Buy
+14,599
New +$819K 0.01% 108

Other funds holding MRK

London Company of Virginia's MRK Position: Q1 2026 in Review

London Company of Virginia reduced its Merck (MRK) stake by 39% in Q1 2026, selling an estimated $172K and leaving 2,378 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #159.

London Company of Virginia first reported a position in MRK in Q2 2015 and has held it in 44 quarters since. The position peaked at $356M in Q4 2022. 3,790 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • London Company of Virginia held 2,378 shares of Merck worth $286K as of Q1 2026.
  • London Company of Virginia sold 1,491 Merck shares in Q1 2026, an estimated $172K.
  • Merck made up ﹤0.01% of London Company of Virginia's portfolio in Q1 2026, its #159 holding.
  • London Company of Virginia first reported a position in Merck in Q2 2015 and has held it in 44 quarters since.
  • London Company of Virginia's Merck position peaked at $356M in Q4 2022.
  • 3,790 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on London Company of Virginia's 13F filing for Q1 2026, filed 15 May 2026.